Osaka, Japan:
- Since its Launch in 2016, New Partnerships Bring Total Global CSR Program Contributions to JPY 19.7 Billion (Approx. USD 140.7 million) Across 24 Programs in 79 Countries
- More Than 23,000 Takeda Employees Voted on New Partnerships Selecting Ipas, Plan International, Pure Earth and United Nations Population Fund (UNFPA)
- Global CSR Program Partnerships Help Takeda Advance Disease Prevention, Empower the Health Workforce and Strengthen Health Systems Across the World
Takeda (TSE:4502/NYSE:TAK) in the present day introduced 4 new partnerships to its Global Corporate Social Responsibility (CSR) Program, which makes long-term commitments to strengthen healthcare for folks in growing and rising nations. Even one of the best clinics and hospitals are unable to supply constant, acceptable, high quality care if folks can’t entry them; a powerful well being workforce, sustainable provide chains, acceptable assets, and way more are key to constructing accessible well being programs. Takeda’s workforce is a important a part of the annual decision-making course of as greater than 23,000 staff voted to choose Ipas, Plan International, Pure Earth and United Nations Population Fund (UNFPA) because the FY2022 Global CSR Program companions.
Since launching in 2016, Takeda’s Global CSR Program has dedicated a complete of JPY 19.7 billion (Approx. USD 140.7 million) to 19 worldwide and non-governmental organizations on 24 long-term applications that tackle greater than 23 Sustainable Development Goal (SDG) Targets in 79 nations. Takeda’s commitments to these new companions in FY2022 embrace:
- JPY 999 million (Approx. USD 7.13 million) to Ipas to implement a four-year program to enhance entry to and use of complete sexual and reproductive well being companies for hard-to-reach ladies and ladies in Ethiopia, Indonesia and Pakistan. By strengthening workforce capability, well being programs and group assist mechanisms, this program will tackle lack of entry to high quality sexual and reproductive well being care which might lead to unintended pregnancies, loss of life and accidents from unsafe abortions, and different potential lack of academic and financial alternatives.
- JPY 497 million (Approx. USD 3.55 million) to Plan Internationalto enhance entry to well being companies for marginalized populations, particularly ladies and ladies experiencing problems from Female Genital Mutilation (FGM), in Somalia. FGM has a major affect on maternal and little one mortality, particularly in rural areas the place there’s a lack of skilled community-based feminine personnel. Over the following 4 years, this program will strengthen well being programs by working cell, important inclusive age-gender-responsive well being care companies, in addition to growing cell/outreach clinic requirements and medical pointers for FGM administration.
- JPY 1 billion (Approx. USD 7.14 million) to Pure Earth to assist shield kids in Colombia, India, Indonesia, Kyrgyzstan and Peru from lead poisoning. Today, 1 in 3 of the world’s kids have sufficient lead in their blood to trigger everlasting mind injury, but many nations lack programs and technical capability to successfully tackle it. By strengthening nations’ well being care programs and coaching well being professionals to determine, monitor, deal with and cut back childhood lead publicity, whereas educating dad and mom, academics and schoolchildren, this five-year program will allow these kids to have higher alternative to attain their full potential.
- JPY 998 million (Approx. USD 7.13 million) to UNFPAto escalate the extent and high quality of case administration assist accessible for survivors of Gender-Based Violence (GBV) in Azerbaijan, El Salvador, Indonesia, Madagascar and Zimbabwe. The four-year program will strengthen social service programs in partnership with studying establishments, governments and civil society; capability constructing, mentoring and monitoring will equip frontline GBV employees to present expert assist for all ladies and ladies together with these most marginalized.
In addition to our FY22 Global CSR Program companions, a portion of the 2022 Global CSR Program has targeted on supporting humanitarian efforts throughout the globe. Takeda is committing JPY 300 million (Approx. USD 2.14 million) to the International Organization for Migration (IOM) to assist the roll-out of the group’s digital Personal Health Record (e-PHR) device for migrants displaced by battle and crises. The device might be deployed in Colombia, Ecuador, Ethiopia, Kenya, Uganda, and Yemen and permits the recording of and entry to medical historical past, diagnoses, and signs throughout borders, well being programs, and languages. This digital resolution goals to attain over 83,000 beneficiaries and will assist improve data about migrants’ well being wants and strengthen nationwide and cross-border illness surveillance and improve response capacities by making well being evaluation information accessible in transit and vacation spot nations.
“We are proud to partner with Ipas, Plan International, Pure Earth and UNPFA to directly respond to some of the most disenfranchised populations’ immediate needs by helping to create infrastructures and systems that effectively address root causes,” says Takako Ohyabu, Takeda’s chief world company affairs and sustainability officer. “These partnerships help reduce life-threatening emergency issues while transforming the daily lives of people and the planet. As a 240-year-old company, we know sustainable impact takes time and we take a long-term view. We also know some of the most enduring, innovative solutions are brought to life through partnerships. We embark on these efforts with our values at heart, enabling our employees to have a direct say in how we tackle these critical global health issues to ultimately help us better serve and empower these communities to be ready for the future.”
Each program helps well being system strengthening in distinctive methods and aligns with nations’ nationwide well being wants. These four- to 10-year funding commitments mirror that there aren’t any fast fixes to a few of the most complicated and longstanding challenges going through well being programs in low- and middle-income nations.
This yr’s companions shared:
- “Ipas is deeply honored to work with Takeda, which shares our commitment to a healthy and just world for all people, to expand access to quality, sustainable sexual and reproductive health care for women and girls in hard-to-reach places. This partnership will strengthen the capacity of health workers, health systems and communities in Ethiopia, Indonesia and Pakistan,” stated Anu Kumar, president and CEO of Ipas.
- “Plan International’s new 5-year partnership with Takeda in Somalia will not only strengthen rural health systems through developing mobile/outreach clinic standards and FGM management clinical guidelines, but also enable Somali girls and women to make decisions about their sexuality and bodies through awareness campaigns and training,” stated Dr. Kiyoko Ikegami, chair of the board of Plan International Japan.
- “Pure Earth is honored to count Takeda as a partner. Together, we will equip five countries to evaluate and identify children currently suffering from lead poisoning, undetected and unseen, so that the healing can begin. This is a powerful example of how public-private partnerships can accelerate solutions. Takeda’s leadership on the childhood lead poisoning crisis is an impactful model to follow,” stated Rich Fuller, CEO of Pure Earth.
- “Gender-based violence is one of the most prevalent human rights violations in the world, with an estimated 1 in 3 women experiencing physical or sexual abuse in their lifetime. It knows no social, economic or national boundaries. With support from Takeda, UNFPA will scale up its efforts to tackle the pandemic of violence against women and girls, providing specialized protection and response services in countries with some of the highest rates of gender-based violence. We are grateful for Takeda’s partnership as we work together to end this global scourge once and for all,” stated Dr. Natalia Kanem, Executive Director of the United Nations Population Fund.
Takeda’s Global CSR Program partnerships have made notable progress because it was initiated in 2016 having:
- Reached greater than 10.5 million direct beneficiaries;
- Trained greater than 60,000 certified well being professionals and group well being employees;
- Provided greater than 1 million group members with focused well being schooling together with on vitamin, water, sanitation, hygiene and sexual and reproductive well being;
- Immunized 4.2 million kids in opposition to preventable illnesses similar to measles; and
- Our companions are on monitor to attain 22 million direct beneficiaries by 2027, offering lifesaving care for weak ladies and newborns, coaching well being employees, stopping illness, strengthening holistic assist for refugees, and a lot extra.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a worldwide, values-based, R&D-driven biopharmaceutical chief headquartered in Japan, dedicated to uncover and ship life-transforming therapies, guided by our dedication to sufferers, our folks and the planet. Takeda focuses its R&D efforts on 4 therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We additionally make focused R&D investments in Plasma-Derived Therapies and Vaccines. We are specializing in growing extremely progressive medicines that contribute to making a distinction in folks’s lives by advancing the frontier of latest therapy choices and leveraging our enhanced collaborative R&D engine and capabilities to create a sturdy, modality-diverse pipeline. Our staff are dedicated to bettering high quality of life for sufferers and to working with our companions in well being care in roughly 80 nations and areas. For extra info, go to https://www.takeda.com.
Important Notice
For the needs of this discover, “release” means this doc, any oral presentation, any query and reply session and any written or oral materials mentioned or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) relating to this launch. This launch (together with any oral briefing and any question-and-answer in reference to it) will not be meant to, and doesn’t represent, symbolize or kind a part of any supply, invitation or solicitation of any supply to buy, in any other case purchase, subscribe for, trade, promote or in any other case get rid of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or different securities are being provided to the general public by way of this launch. No providing of securities shall be made in the United States besides pursuant to registration below the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This launch is being given (along with any additional info which can be supplied to the recipient) on the situation that it’s for use by the recipient for info functions solely (and not for the analysis of any funding, acquisition, disposal or every other transaction). Any failure to adjust to these restrictions might represent a violation of relevant securities legal guidelines. The firms in which Takeda straight and not directly owns investments are separate entities. In this launch, “Takeda” is typically used for comfort the place references are made to Takeda and its subsidiaries in basic. Likewise, the phrases “we,” “us” and “our” are additionally used to refer to subsidiaries in basic or to those that work for them. These expressions are additionally used the place no helpful function is served by figuring out the actual firm or firms.
Forward-Looking Statements
This press launch and any supplies distributed in reference to this press launch might include forward-looking statements, beliefs or opinions relating to Takeda’s future business, future place and outcomes of operations, together with estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements typically embrace phrases similar to “targets,” “plans,” “believes,” “hopes,” “continues,” “expects,” “aims,” “intends,” “ensures,” “will,” “may,” “should,” “would,” “could” “anticipates,” “estimates,” “projects” or comparable expressions or the unfavorable thereof. These forward-looking statements are based mostly on assumptions about many essential elements, together with the next, which might trigger precise outcomes to differ materially from these expressed or implied by the forward-looking statements: the financial circumstances surrounding Takeda’s world business, together with basic financial situations in Japan and the United States; aggressive pressures and developments; modifications to relevant legal guidelines and laws, together with world well being care reforms; challenges inherent in new product growth, together with uncertainty of medical success and selections of regulatory authorities and the timing thereof; uncertainty of economic success for new and present merchandise; manufacturing difficulties or delays; fluctuations in curiosity and forex trade charges; claims or issues relating to the security or efficacy of marketed merchandise or product candidates; the affect of well being crises, just like the novel coronavirus pandemic, on Takeda and its prospects and suppliers, together with overseas governments in nations in which Takeda operates, or on different sides of its business; the timing and affect of post-merger integration efforts with acquired firms; the power to divest belongings that aren’t core to Takeda’s operations and the timing of any such divestment(s); and different elements recognized in Takeda’s most up-to-date Annual Report on Form 20-F and Takeda’s different studies filed with the U.S. Securities and Exchange Commission, accessible on Takeda’s web site at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda doesn’t undertake to replace any of the forward-looking statements contained in this press launch or every other forward-looking statements it might make, besides as required by regulation or inventory trade rule. Past efficiency will not be an indicator of future outcomes and the outcomes or statements of Takeda in this press launch is probably not indicative of, and will not be an estimate, forecast, assure or projection of Takeda’s future outcomes.
Exchange Rates
In this press launch, sure quantities offered in Japanese yen have been translated to US {dollars} solely for the comfort of the reader. Except the place in any other case famous, these comfort translations have been made at an trade price of 1USD = 140.03 JPY, the Noon Buying Rate licensed by the Federal Reserve Bank of New York on September 2, 2022. The price and methodologies used for these comfort translations differ from the forex trade charges and translation methodologies below International Financial Reporting Standards used for the preparation of Takeda’s consolidated monetary statements. These translations shouldn’t be construed as a illustration that the related Japanese yen quantities might be transformed into U.S. {dollars} at this or every other price.
Medical info
This press launch comprises details about merchandise that is probably not accessible in all nations, or could also be accessible below totally different logos, for totally different indications, in totally different dosages, or in totally different strengths. Nothing contained herein must be thought of a solicitation, promotion or commercial for any pharmaceuticals together with those below growth.
View supply model on businesswire.com: https://www.businesswire.com/news/home/20220913005811/en/
